Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen

被引：0
|
作者：
Davies, C [1 ]
机构：
[1] Univ Oxford, Studies Unit, Clin Trial Serv & Epidemiol, Oxford, England
来源：
CANCER TREATMENT REVIEWS | 2004年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.ctrv.2004.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：583 / 588
页数：6
相关论文
共 50 条
  • [21] Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen
    Bertelli, G.
    Hall, E.
    Ireland, E.
    Snowdon, C. F.
    Jassem, J.
    Drosik, K.
    Karnicka-Mlodkowska, H.
    Coombes, R. C.
    Bliss, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 498 - 505
  • [22] The effects on lipids of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
    Gonnelli, S.
    Montagnani, A.
    Cadirni, A.
    Caffarelli, C.
    Montomoli, M.
    Campagna, M. S.
    Petrioli, R.
    Del Santo, K.
    Cuda, C.
    Nuti, R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 409 - 409
  • [23] Potential clinical and economic impact of switching US women to exemestane following 2-3 years of therapy with tamoxifen for early breast cancer.
    Thompson, D.
    Taylor, D. C.
    Montoya, E. L.
    Jones, S. E.
    Weinstein, M. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 327S - 327S
  • [24] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. (vol 369, pg 559, 2007)
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    LANCET, 2007, 369 (9565): : 906 - 906
  • [25] The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer
    Jones, Stephen
    Stokoe, Christopher
    Sborov, Mark
    Braun, Marcus
    Ethirajan, Sukumar
    Kutteh, Leila
    Pippen, John
    Patel, Mrugesh
    Paul, Devchand
    Blum, Joanne L.
    Holmes, Frankie Ann
    Myron, Mark C.
    Cantrell, James
    Hartung, Nichole L.
    Look, Regan M.
    Di Salle, Enrico
    Davis, Jennifer C.
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL BREAST CANCER, 2008, 8 (06) : 527 - 532
  • [26] Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer.
    Thompson, D
    Taylor, DCA
    Montoya, EL
    Winer, E
    Weinstein, MC
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S218 - S218
  • [27] 10 year event-free survival (EFS) in postmenopausal women with early stage breast cancer during the second five years after adjuvant tamoxifen.
    Kennecke, H
    Speers, C
    Chia, S
    Norris, B
    Gelmon, K
    Bryce, C
    Barnett, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S57 - S58
  • [28] The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
    Montagnani, A.
    Gonnelli, S.
    Cadirni, A.
    Caffarelli, C.
    Del Santo, K.
    Pieropan, C.
    Campagna, M. S.
    Montomoli, M.
    Petrioli, R.
    Nuti, R.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2008, 19 (08) : 592 - 597
  • [29] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Nils Wilking
    Stig Holmberg
    Linus Jönsson
    Breast Cancer Research and Treatment, 2007, 102 : 289 - 299
  • [30] Overall survival and disease-free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms
    Feng, Ruigang
    Huang, Wenwen
    Min, Jie
    Shu, Wenjun
    Zhang, Yanshou
    Yu, Yue
    Cao, Xuchen
    Wang, Xin
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2024,
12345